首页> 外文OA文献 >Proliferative Glomerulonephritis with Monoclonal Immunoglobulin G Lambda Deposits: Report of the First Pediatric Case
【2h】

Proliferative Glomerulonephritis with Monoclonal Immunoglobulin G Lambda Deposits: Report of the First Pediatric Case

机译:具有单克隆免疫球蛋白GLAMBDA沉积物的增殖性肾小球肾炎:第一个儿科案例的报告

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Proliferative glomerulonephritis with monoclonal immunoglobulin G deposits (PGNMID) is a recently described, uncommon renal disorder which is considered a monoclonal gammopathy of renal significance. Although some patients will have a detectable monoclonal spike, overt hematologic malignancy is found in only a minority. Most patients with PGNMID are over the age of 50 years, and to our knowledge no cases have been reported in children or adolescents. Renal biopsy shows variable histologic patterns by light microscopy, with membranoproliferative and membranous patterns being most common. Immunofluorescence microscopy demonstrates restriction to a single immunoglobulin G heavy chain isotype and a single light chain subtype. Electron microscopy reveals granular, unorganized deposits. We report a rare pediatric case which occurred in a 17-year-old female. The rarity of this entity in the adult population has not permitted a standard treatment regimen to be established. Our adolescent patient was treated with multiple treatment regimens including prednisone, mycophenolate mofetil, rituximab, bortezomib, and daratumumab. Our case demonstrates that awareness of this disorder by pediatric nephrologists and pathologists is vital to guide accurate disease classification, prognosis, and treatment.
机译:具有单克隆免疫球蛋白G沉积物(PGNMID)的增殖性肾小球肾炎是最近描述的,罕见的肾病紊乱,被认为是肾性意义的单克隆血舌。虽然有些患者将具有可检测的单克隆尖峰,但公开的血液学恶性肿瘤仅在少数群体中发现。大多数患有PGNMID的患者超过50岁,并且在儿童或青少年没有报告任何案件。肾活检显示通过光学显微镜显微镜的可变组织学模式,膜上载体和最常见的膜状模式。免疫荧光显微镜显着证明对单个免疫球蛋白G重链同种型和单个轻链亚型的限制。电子显微镜显示粒状,无组织沉积物。我们举报了一个在17岁的女性中发生的罕见的儿科案例。该实体在成年人群体中的稀有性尚未允许建立标准治疗方案。我们的青少年患者被多种治疗方案治疗,包括泼尼松,霉酚酸酯Mofetil,Rituximab,Bortezomib和DarataTumumab。我们的病例表明,儿科肾病学家和病理学家对这种疾病的认识至关重要,对指导准确的疾病分类,预后和治疗至关重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号